Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load - PubMed (original) (raw)
doi: 10.1016/j.ymthe.2004.03.005.
Gwendolyn K Binder, Xiaobin Lu, Vladimir Slepushkin, Randall Merling, Patricia Echeagaray, Mario Pereira, Tatiana Slepushkina, Scott Barnett, Lesia K Dropulic, Richard Carroll, Bruce L Levine, Carl H June, Boro Dropulic
Affiliations
- PMID: 15194057
- DOI: 10.1016/j.ymthe.2004.03.005
Free article
Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load
Laurent M Humeau et al. Mol Ther. 2004 Jun.
Free article
Abstract
We present preclinical studies that demonstrate in vitro the feasibility and efficacy of lentivirus-based vector antisense gene therapy for control of HIV replication in primary T lymphocytes isolated from HIV-infected patients discordant for clinical status. VRX496 is a VSV-G-pseudotyped HIV-based vector that encodes an antisense payload against the HIV envelope gene. The antisense payload is under the control of the native LTR promoter, which is highly transactivated by tat upon HIV infection in the cell. Transfer of autologous CD4(+) T lymphocytes genetically modified with VRX496 (VRX496T) into HIV-infected patients is intended to provide a reservoir of cells capable of controlling HIV, potentially delaying AIDS onset. To determine the patient population likely to respond to VRX496 for optimal efficacy, we examined the ability of our research vector, VRX494, to modify and suppress HIV in vitro in lymphocytes isolated from 20 study subjects discordant for CD4 count and viral load. VRX494 is analogous to the clinical vector VRX496, except that it contains GFP as a marker gene instead of the 186-tag marker in the clinical vector. To transfer VRX494 to target cells we developed a novel scalable two-step transduction procedure that has been translated to the clinic in an ongoing clinical trial. This procedure achieved unprecedented transduction efficiencies of 94 +/- 5% in HIV(+) study subject cells. In addition the vector inhibited HIV replication >/=93% in culture regardless of the viral load or CD4 count of the subject or tropism of the virus strain with which they were infected. These findings demonstrate that VRX496T therapy is expected to be beneficial to patients that differ in their status in term of CD4 count and viral load. The methods described represent significant technical advances facilitating execution of lentivirus vector-mediated gene therapy for treatment of HIV and are currently being employed in the first trial evaluating lentivirus vector safety in humans.
Similar articles
- Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol.
Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B. Lu X, et al. J Gene Med. 2004 Sep;6(9):963-73. doi: 10.1002/jgm.593. J Gene Med. 2004. PMID: 15352069 - Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.
Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang WT, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH. Tebas P, et al. Blood. 2013 Feb 28;121(9):1524-33. doi: 10.1182/blood-2012-07-447250. Epub 2012 Dec 20. Blood. 2013. PMID: 23264589 Free PMC article. Clinical Trial. - Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection.
Morris KV, Rossi JJ. Morris KV, et al. Curr HIV Res. 2004 Apr;2(2):185-91. doi: 10.2174/1570162043484906. Curr HIV Res. 2004. PMID: 15078182 Review. - CD4 down modulation on T-cells: an 'immune' checkpoint for HIV.
Marodon G. Marodon G. Immunol Lett. 2001 Dec 3;79(3):165-8. doi: 10.1016/s0165-2478(01)00286-3. Immunol Lett. 2001. PMID: 11600193 Review.
Cited by
- Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs.
Agosto LM, Liszewski MK, Mexas A, Graf E, Pace M, Yu JJ, Bhandoola A, O'Doherty U. Agosto LM, et al. Virology. 2011 Jan 5;409(1):46-53. doi: 10.1016/j.virol.2010.08.024. Virology. 2011. PMID: 20970154 Free PMC article. - HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model.
Mukherjee R, Plesa G, Sherrill-Mix S, Richardson MW, Riley JL, Bushman FD. Mukherjee R, et al. Mol Ther. 2010 Apr;18(4):803-11. doi: 10.1038/mt.2009.316. Epub 2010 Jan 26. Mol Ther. 2010. PMID: 20104212 Free PMC article. - Standardization of a cytometric p24-capture bead-assay for the detection of main HIV-1 subtypes.
Merbah M, Onkar S, Grivel JC, Vanpouille C, Biancotto A, Bonar L, Sanders-Buell E, Kijak G, Michael N, Robb M, Kim JH, Tovanabutra S, Chenine AL. Merbah M, et al. J Virol Methods. 2016 Apr;230:45-52. doi: 10.1016/j.jviromet.2016.01.009. Epub 2016 Jan 22. J Virol Methods. 2016. PMID: 26808359 Free PMC article. - The use of cell-delivered gene therapy for the treatment of HIV/AIDS.
Symonds GP, Johnstone HA, Millington ML, Boyd MP, Burke BP, Breton LR. Symonds GP, et al. Immunol Res. 2010 Dec;48(1-3):84-98. doi: 10.1007/s12026-010-8169-7. Immunol Res. 2010. PMID: 20737298 Review. - Regulatable gene expression systems for gene therapy applications: progress and future challenges.
Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, Curtin JF, Soffer EB, Mondkar S, King GD, Hu J, Sciascia SA, Candolfi M, Greengold DS, Lowenstein PR, Castro MG. Goverdhana S, et al. Mol Ther. 2005 Aug;12(2):189-211. doi: 10.1016/j.ymthe.2005.03.022. Mol Ther. 2005. PMID: 15946903 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials